drugset / Trial / NCT03975036
Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody
NaSingle-groupOpen-labelTreatment
Summary
The main objective was to evaluate the safety and efficacy of anlotinib hydrochloride combined with pd-1 antibody second-line and above in the treatment of advanced solid tumors
Timeline
- Start
- 2019-04-08
- Primary completion
- 2020-06-08
- Completion
- 2021-07-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 10 mg | Oral |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |